DMRA
Damora Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.35 / 10
Outperform
Sentiment is upbeat (6.35/10) and fund flow strong (8.07/10), especially in small‑to‑large investors. Yet price fell 36.8% and analyst coverage is limited to two strong‑buy calls, creating mixed confidence.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-17
InstitutionGuggenheim
Times predicted3
Historical Win Rate66.7%
What is the analyst consensus for DMRA?
- DMRA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.35/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
